These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 26670218)

  • 21. "I just believe there is a risk" understanding of undetectable equals untransmissible (U = U) among health providers and HIV-negative partners in serodiscordant relationships in Kenya.
    Ngure K; Ongolly F; Dolla A; Awour M; Mugwanya KK; Irungu E; Mugo N; Bukusi EA; Morton J; Odoyo J; Wamoni E; Barnabee G; Peebles K; O'Malley G; Baeten JM;
    J Int AIDS Soc; 2020 Mar; 23(3):e25466. PubMed ID: 32144888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya.
    Maina EK; Mureithi H; Adan AA; Muriuki J; Lwembe RM; Bukusi EA
    Int J Infect Dis; 2020 Aug; 97():151-158. PubMed ID: 32497804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
    Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
    J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.
    Suaysod R; Ngo-Giang-Huong N; Salvadori N; Cressey TR; Kanjanavanit S; Techakunakorn P; Krikajornkitti S; Srirojana S; Laomanit L; Chalermpantmetagul S; Lallemant M; Le Cœur S; McIntosh K; Traisathit P; Jourdain G
    Clin Infect Dis; 2015 Jul; 61(1):95-101. PubMed ID: 25838288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.
    Haberer JE; Musinguzi N; Boum Y; Siedner MJ; Mocello AR; Hunt PW; Martin JN; Bangsberg DR
    J Acquir Immune Defic Syndr; 2015 Dec; 70(4):386-92. PubMed ID: 26110445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High Transmitter CD4+ T-Cell Count Shortly after the Time of Transmission in a Study of African Serodiscordant Couples.
    Karita E; Price MA; Lakhi S; Kilembe W; Kamali A; Ruzagira E; Hunter E; Farmer P; Allen S; Stevens G; Chetty P; Welsh S; Yang A; Gilmour J; Fast P;
    PLoS One; 2015; 10(8):e0134438. PubMed ID: 26291456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
    Abgrall S; Duval X; Joly V; Descamps D; Matheron S; Costagliola D;
    Clin Infect Dis; 2003 Dec; 37(11):1517-26. PubMed ID: 14614675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya.
    Kadima J; Patterson E; Mburu M; Blat C; Nyanduko M; Bukusi EA; Cohen C; Oyaro P; Abuogi L
    PLoS One; 2018; 13(11):e0200242. PubMed ID: 30412576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virologic suppression in nevirapine-exposed HIV-infected infants initiating antiretroviral therapy in rural Uganda.
    Kay J; Wanzira H; Sandison T; Kakuru A; Bigira V; Kamya M; Homsy J; Tappero JW; Havlir D; Dorsey G; Ruel T
    J Trop Pediatr; 2012 Jun; 58(3):194-9. PubMed ID: 21930666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
    Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
    Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
    HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High rates of viral suppression in adults and children with high CD4+ counts using a streamlined ART delivery model in the SEARCH trial in rural Uganda and Kenya.
    Kwarisiima D; Kamya MR; Owaraganise A; Mwangwa F; Byonanebye DM; Ayieko J; Plenty A; Black D; Clark TD; Nzarubara B; Snyman K; Brown L; Bukusi E; Cohen CR; Geng EH; Charlebois ED; Ruel TD; Petersen ML; Havlir D; Jain V
    J Int AIDS Soc; 2017 Jul; 20(Suppl 4):21673. PubMed ID: 28770596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence to recommendations for ART and targeted PrEP use among HIV serodiscordant couples in East Africa: the "PrEP as a bridge to ART" strategy.
    Musinguzi N; Kidoguchi L; Mugo NR; Ngure K; Katabira E; Celum CL; Baeten JM; Heffron R; Haberer JE;
    BMC Public Health; 2020 Oct; 20(1):1621. PubMed ID: 33115478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does gender or mode of HIV acquisition affect virological response to modern antiretroviral therapy (ART)?
    Saunders P; Goodman AL; Smith CJ; Marshall N; O'Connor JL; Lampe FC; Johnson MA
    HIV Med; 2016 Jan; 17(1):18-27. PubMed ID: 26140659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virologic outcomes in early antiretroviral treatment: HPTN 052.
    Eshleman SH; Wilson EA; Zhang XC; Ou SS; Piwowar-Manning E; Eron JJ; McCauley M; Gamble T; Gallant JE; Hosseinipour MC; Kumarasamy N; Hakim JG; Kalonga B; Pilotto JH; Grinsztejn B; Godbole SV; Chotirosniramit N; Santos BR; Shava E; Mills LA; Panchia R; Mwelase N; Mayer KH; Chen YQ; Cohen MS; Fogel JM
    HIV Clin Trials; 2017 May; 18(3):100-109. PubMed ID: 28385131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda.
    Musinguzi N; Mocello RA; Boum Y; Hunt PW; Martin JN; Haberer JE; Bangsberg DR; Siedner MJ
    AIDS Behav; 2017 Jun; 21(6):1735-1740. PubMed ID: 27256394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.
    Geretti AM; Harrison L; Green H; Sabin C; Hill T; Fearnhill E; Pillay D; Dunn D;
    Clin Infect Dis; 2009 May; 48(9):1296-305. PubMed ID: 19331585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.
    Ying R; Sharma M; Heffron R; Celum CL; Baeten JM; Katabira E; Bulya N; Barnabas RV
    J Int AIDS Soc; 2015; 18(4 Suppl 3):20013. PubMed ID: 26198348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Since both of us are using antiretrovirals, we have been supportive to each other": facilitators and barriers of pre-exposure prophylaxis use in heterosexual HIV serodiscordant couples in Kisumu, Kenya.
    Patel RC; Stanford-Moore G; Odoyo J; Pyra M; Wakhungu I; Anand K; Bukusi EA; Baeten JM; Brown JM
    J Int AIDS Soc; 2016; 19(1):21134. PubMed ID: 27964776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.